MétaCan
Menu
Back to cohort
Record W4404298071 · doi:10.1093/jnci/djae281

Supporting evidence in phase 2 cancer trial protocols: a content analysis

2024· article· en· W4404298071 on OpenAlexafffund
Selin Bicer, Angela Nelson, Katerina Carayannis, Jonathan Kimmelman

Bibliographic record

VenueJNCI Journal of the National Cancer Institute · 2024
Typearticle
Languageen
FieldMathematics
TopicStatistical Methods in Clinical Trials
Canadian institutionsMcGill University
FundersCanadian Institutes of Health Research
KeywordsProtocol (science)Clinical trialMedicineAttritionSample size determinationEvidence-based practiceTypologyEvidence-based medicineMedical physicsAlternative medicineInternal medicineStatisticsPathology

Abstract

fetched live from OpenAlex

BACKGROUND: Phase 2 trials are instrumental for designing definitive efficacy trials or attaining accelerated approval. However, high attrition of drug candidates in phase 2 trials raises questions about their supporting evidence. METHODS: We developed a typology of supporting evidence for phase 2 cancer trials. We also devised a scheme for capturing elements that enable an assessment of the strength of such evidence. Using this framework, we content analyzed supporting evidence provided in protocols of 50 randomly sampled phase 2 cancer monotherapy trials between January 2014 and January 2019, available on ClinicalTrials.gov. RESULTS: Of the 50 protocols in our sample, 52% were industry funded. Most invoked supporting evidence deriving from trials against different cancers (n = 28, 56%) or preclinical studies (n = 48, 96%) but not from clinical studies involving the target drug-indication pairing (n = 23, 46%). When presenting evidence from models, only 1 (2%) protocol explained its translational relevance. Instead, protocols implied translatability by describing molecular (86%) and pathophysiological (84%) processes shared by model and target systems. Protocols often provided information for assessing the magnitude, precision, and risk of bias for supporting trials (n = 43; 93%, 91%, 47%, respectively). However, such information was often unavailable for preclinical studies (n = 49; 53%, 22%, 59%, respectively). CONCLUSIONS: Supporting evidence is key to justifying the commitment of scientific resources and patients to a clinical hypothesis. Protocols often omit elements that would enable critical assessment of supporting evidence for phase 2 monotherapy cancer trials. These gaps suggest the promise of more structured approaches for presenting supporting evidence.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Direct model labels (unvalidated)

Per-model category and study-design labels from the labeling rounds. They are machine output, unvalidated, and the disagreement between models ships as data. No study design here is MEDLINE-validated yet.

Model armCategoriesStudy designConfidence
gemmaMetaresearch
Domain: Reporting · Genre: Empirical
About the Canadian research system: no · About a Canadian topic: no
Observationallow
gptMetaresearch
Domain: Reporting · Genre: Empirical
About the Canadian research system: no · About a Canadian topic: no
Observationallow
models agreeAgreement compares identical category sets and study designs across arms.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.008
metaresearch head score (Gemma)0.094
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: Theoretical or conceptual
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.464
Threshold uncertainty score0.914

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0080.094
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.906
GPT teacher head0.726
Teacher spread0.179 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Labeled directly by 2 models reading the full record.

Study designObservational
DomainReporting
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueJNCI Journal of the National Cancer InstituteSame topicStatistical Methods in Clinical TrialsCategoryMetaresearchFrench-language works237,207